SCHEMBL6348783

SCHEMBL6348783

CC(=O)Nc1ccc(S(=O)(=O)c2ccc(NC(=O)C(C)(C)OC(C)=O)c(Cl)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB11 O95342 1/20 0.53
PKM P14618 2/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49
CYP2C19 P33261 1/20 0.49
PDK1 Q15118 6/20 0.48
PDK2 Q15119 6/20 0.48
PDK3 Q15120 6/20 0.48
PDK4 Q16654 6/20 0.48
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPT P10636 1/20 0.45
NPC1 O15118 1/20 0.44
GAA P10253 1/20 0.44
ABCC9 O60706 1/20 0.43
ABCC8 Q09428 1/20 0.43
KCNJ11 Q14654 1/20 0.43
KCNJ8 Q15842 1/20 0.43
IDO1 P14902 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6473333 0.92 MAPT (0.56) ABCB11CA1CA2CA9PDK1
SCHEMBL6347588 0.89 PDK1 (0.50) ABCB11CA1CA2CA9CYP2C19
SCHEMBL6449596 0.86 ABCB11 (0.59) ABCB11PKMCA1CA2CA9
SCHEMBL27533287 0.86 RORC (0.47) CA1CA2CA9PDK1PDK2
SCHEMBL5737386 0.82 PDK1 (0.66) ABCB11CA1CA2CA9PDK1
SCHEMBL6350096 0.82 ABCB11 (0.76) ABCB11CYP2C19PDK1PDK2PDK3
SCHEMBL6350091 0.82 ABCB11 (0.76) ABCB11CYP2C19PDK1PDK2PDK3
SCHEMBL6348397 0.81 PAX8 (0.40) CA1CA2CA9PDK1PDK2
SCHEMBL6572441 0.77 MAPT (0.63) ABCB11CA1CA2CA9PDK1
SCHEMBL27533267 0.74 PDK1 (0.44) CA1CA2CA9PDK1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960688-B2 Use of compounds for the elevation of pyruvate dehydrogenase activity ASTRAZENECA AB (SE) 2005-11-01 US disclosed
EP-1082110-B1 USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY ASTRAZENECA AB (SE) 2004-03-24 EP disclosed
US-20040009979-A1 Use of compounds for the elevation of pyruvate dehydrogenase activity ZENECA LIMITED 2004-01-15 US disclosed
US-6498275-B1 Use of compounds for the elevation of pyruvate dehydrogenase activity ASTRAZENECA AB (SE) 2002-12-24 US disclosed
CN-1303281-A Application of compound in enhancing activity of pyruvate dehydrogenase ASTRA ZENECA LTD (SE) 2001-07-11 CN disclosed
EP-1082110-A1 USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY AstraZeneca AB (SE) 2001-03-14 EP disclosed
WO-1999062506-A1 USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY ASTRAZENECA AB (SE) 1999-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009979-A1 Use of compounds for the elevation of pyruvate dehydrogenase activity PDHA1, PDK1, PDHB ABCB11 325/4885PKM 30/4885CA1 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.